Tag

Obesity Treatment

All articles tagged with #obesity treatment

health2 days ago•2 min saved

CBL-514 Injection Triggers Fat Cell Death to Cut Visceral Fat by 12%

An experimental injection called CBL-514 has shown promising results in early human trials for reducing visceral fat, the dangerous fat surrounding internal organs. Unlike existing weight-loss drugs that suppress appetite, CBL-514 triggers apoptosis, a process where fat cells self-destruct. Phase 2 trials reported a 12% reduction in visceral fat volume within four weeks of treatment, with effects persisting after the injections ended. The drug, developed by Caliway Biopharmaceuticals, is now entering Phase 3 trials to test its safety and efficacy in larger populations.

via Fox News|

#apoptosis #cbl-514 #clinical-trials

health4 days ago•5 min saved

New Study Links GLP-1 Drugs to Higher Rates of Nail Detachment and Hair Loss

A cross-sectional study of 1,904 participants across four countries found that GLP-1 users reported nail detachment at a rate of 39%, compared to 9% of non-users. While the association is strong, researchers caution that weight loss and nutritional deficiencies may be the primary drivers rather than the drugs themselves.

via ScienceAlert|

#dermatology #glp-1 #hair-loss

health-and-science7 days ago•7 min saved

New Mouse Study Links Semaglutide to Slower Aging and Longer Lifespan

A new study in Nature demonstrates that semaglutide, a GLP-1 receptor agonist, slows aging and extends lifespan in female mice. While these drugs are approved for diabetes and obesity, emerging evidence suggests they offer broader therapeutic benefits beyond weight loss and glucose control, though the specific mechanisms remain unclear.

via Nature|

#aging-research #glp-1-agonists #health-and-science

health9 days ago•17 min saved

Trump's 'Fat Drug' Nickname Sparks Backlash from Doctors and Patients Over Stigma and Access

President Donald Trump’s repeated use of the terms 'fat shots' and 'fat drugs' to describe GLP-1 medications has drawn sharp criticism from medical professionals and patients. While the administration has worked to lower drug prices, critics argue the language stigmatizes obesity and ignores the medications' broad therapeutic benefits. Users report that these drugs are life-changing for conditions beyond weight loss, including diabetes and heart disease, and urge policymakers to focus on expanding Medicaid coverage rather than using derogatory terminology.

via HuffPost|

#donald-trump #glp-1-medications #health

health9 days ago•2 min saved

CBL-514 Enters Phase 3 Trials After Phase 2 Data Shows 12% Visceral Fat Reduction

CBL-514, a new injectable weight-loss drug, has entered Phase 3 clinical trials after Phase 2 results demonstrated significant reductions in visceral and subcutaneous fat. Unlike GLP-1 agonists that suppress appetite, CBL-514 induces apoptosis in fat cells, potentially offering a more permanent solution to weight regain. Early data shows a 12% drop in visceral fat within four weeks, with effects persisting after treatment cessation.

via New York Post|

#caliway-biopharmaceuticals #cbl-514 #glp-1-alternatives

health-and-science11 days ago•1 min saved

CBL-514 Enters Phase 3 After Phase 2 Data Shows 12% Visceral Fat Reduction

CBL-514, a first-in-class injectable that induces fat cell death, has advanced to Phase 3 trials after Phase 2 data demonstrated significant reductions in visceral and subcutaneous fat. Unlike GLP-1 drugs that suppress appetite, CBL-514 acts locally to destroy adipocytes, potentially preventing weight regain. Presented at the EASD 2026 meeting, the drug showed a 12% drop in visceral fat at week 4, with sustained effects at week 12, and is being developed by Caliway Biopharmaceuticals.

via Medscape|

#caliway-biopharmaceuticals #cbl-514 #glp-1-alternatives

health-and-science12 days ago•3 min saved

Eli Lilly Unveils Retatrutide and EloraTZP Data, Showcasing Massive Weight Loss and New Side Effect Profiles

Eli Lilly has released new Phase 3 data for its triple-agonist drug retatrutide, showing that even the lowest dose yields significant weight loss, while a new combination therapy, EloraTZP, demonstrates even greater efficacy but with higher dropout rates due to side effects.

via New York Post|

#eli-lilly #eloratzp #glp-1

healthcare12 days ago•0 min saved

Lilly's Retatrutide and EloraTZP Set New Weight-Loss Benchmarks at EASD

Eli Lilly reported that its experimental triple-agonist retatrutide caused an average weight loss of 49.6 pounds in patients with Type 2 diabetes, while a new combination therapy, EloraTZP, achieved up to 54.1 pounds of loss. Both drugs target multiple gut hormones to enhance satiety and metabolic control, with retatrutide expected to seek FDA approval by March 2027.

via USA Today|

#eli-lilly #eloratzp #glp-1

health-and-science13 days ago•3 min saved

Novo Nordisk data shows Wegovy pill sustains weight loss after injection switch

Novo Nordisk presented real-world data indicating that patients switching from injectable obesity drugs to the new oral Wegovy pill continued losing weight. The analysis suggests the pill may offer convenience without sacrificing efficacy, potentially shifting patient preference away from weekly injections.

via CNBC|

#cagrisema #glp-1-drugs #health-and-science

health13 days ago•4 min saved

GLP-1 Switches Require Individualized Titration and Close Monitoring

Primary care providers are increasingly managing transitions between GLP-1 receptor agonists and dual incretin agents due to insurance changes, side effects, or efficacy issues. Experts emphasize that switching is not a simple swap; it requires careful planning around drug half-lives, individualized dose titration, and close monitoring for hypoglycemia. While these medications are highly effective, up to 15% of patients may see minimal results, and long-term success depends on combining medication with lifestyle changes.

via Medscape|

#clinical-guidelines #glp-1-receptor-agonists #health

health14 days ago•396 min saved

Eli Lilly’s Retatrutide Sets New Weight Loss Records in Phase 3 Trials

Eli Lilly’s experimental triple-agonist drug, retatrutide, has demonstrated unprecedented weight loss in late-stage clinical trials. In a phase 3 study for patients with Type 2 diabetes, participants lost up to 23% of their body weight, while those with obesity but no diabetes lost up to 25%. The drug targets three hormones, including glucagon, to enhance metabolic effects beyond existing GLP-1 therapies. Lilly plans to file for FDA approval early next year, though unapproved versions are already circulating.

via NBC News|

#eli-lilly #glp-1-agonists #health

health16 days ago•0 min saved

New Data Shows Oral GLP-1 Drug Effective for Weight Loss in Women Across All Menopausal Stages

A post hoc analysis of two major clinical trials indicates that orforglipron, an oral non-peptide GLP-1 receptor agonist, produces significant weight loss in women with obesity regardless of their menopausal status. Presented at the European Association for the Study of Diabetes (EASD) 2026 in Milan, the findings suggest the drug’s efficacy remains consistent whether patients are premenopausal, perimenopausal, or postmenopausal. In the ATTAIN-1 trial, which excluded patients with diabetes, women lost between 12.81% and 14.38% of their body weight on the 36 mg dose, compared to less than 1.02% on placebo. Similarly, in ATTAIN-2, which included patients with type 2 diabetes, weight loss ranged from 8.88% to 13.62% depending on menopausal stage. Over 80% of women in the non-diabetic trial achieved at least a 5% weight reduction, a figure far higher than the 20-25% seen in the placebo group. The study also noted improvements in waist-to-height ratios across most subgroups. While the results highlight broad applicability for women across different life stages, the analysis was supported by Eli Lilly, the manufacturer of orforglipron, and all authors were company employees.

via Medscape|

#easd-2026 #glp-1-agonist #health

health18 days ago•4 min saved

GLP-1 Non-Responders: Scientists Probe Hormonal and Genetic Drivers of Variable Weight Loss

While GLP-1 medications like semaglutide and tirzepatide help many patients lose significant weight, 10–15% of users experience minimal or no results. Researchers are investigating why this occurs, with early evidence pointing to biological sex, oestrogen levels, and genetic factors as key drivers of individual response. The Endocrine Society has designated understanding this heterogeneity as a priority to enable personalized treatments.

via Nature|

#endocrine-society #glp-1-drugs #health

health28 days ago•5 min saved

New Study: GLP-1 Drugs Primarily Burn Fat While Preserving Muscle Mass

A new study presented at the European Congress on Obesity indicates that 80-85% of weight lost via GLP-1 drugs comes from fat, with skeletal muscle mass largely preserved. While some experts warn of lean mass loss, this research suggests favorable body composition changes.

via SciTechDaily|

#body-composition #glp-1-drugs #health

health2 months ago•7 min saved

GLP-1 Weight-Loss Drugs Quietly Trim Cravings for Alcohol

Weight‑loss meds like Wegovy, Ozempic, and Mounjaro (GLP-1 agonists) may also dampen alcohol cravings and consumption for some users. Reports and early studies show people drinking less—some with strong nausea or fullness after alcohol—while others notice little change. While these effects could aid weight loss and alter drinking habits, safety concerns, potential off-label use for alcohol use disorder, and the need for larger, longer studies mean regulators haven’t endorsed using these drugs for addiction treatment beyond obesity/diabetes populations.

via BBC|

#alcohol-use #glp-1 #health